Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb 7:2020:8152640.
doi: 10.1155/2020/8152640. eCollection 2020.

Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes

Bing-Li Liu  1 , Xiao-Mei Liu  1 , Yi-Fei Ren  1 , Yi-Xuan Sun  1 , Meng-Hui Luo  1 , Lei Ye  2 , Jian-Hua Ma  1 , Feng-Fei Li  1
Affiliations
Randomized Controlled Trial

Sexual Differences in response to Mid- or Low-Premixed Insulin Analogue in Patients with Type 2 Diabetes

Bing-Li Liu et al. J Diabetes Res. .

Abstract

Objective: To observe whether there are sexual-related differences in response to mid- or low-premixed insulin in type 2 diabetic patients.

Methods: This was an analysis of CGM data of a previous study. After screening, patients with longstanding T2D receive a 7-day continuous subcutaneous insulin infusion (CSII) therapy, and then subjects were randomly assigned 1 : 1 into two groups receiving Novo Mix 30 or Humalog Mix 50 regimen for a 2-day phage, followed by a 4-day cross-over period. A 4-day continuous glucose monitoring (CGM) was performed during the cross-over period. The primary endpoint was the differences in glycemic control between male and female patients receiving mid- or low-premixed insulin therapy.

Results: A total of 102 patients (52 men and 50 women) completed the study. Our data showed that male patients had significant decrease in mean glucose levels monitored by CGM after three meals during Humalog Mix 50 treatment period compared to those received Novo Mix 30 regimen (0900: 11.0 ± 2.5 vs. 12.2 ± 2.8, 1000: 9.9 ± 2.9 vs. 11.3 ± 3.1, 1200: 8.0 ± 1.9 vs. 9.1 ± 2.5, 1400: 9.2 ± 2.3 vs. 10.3 ± 2.5, and 2000: 7.3 ± 2.1 vs. 8.2 ± 2.4 mmol/L, p < 0.05, respectively). In addition, male patients receiving Novo Mix 30 experienced a significantly increased hypoglycemic duration compared to those of receiving Humalog Mix 50 (0 (0, 4.8) vs. 0 (0, 0), p < 0.05, respectively). In addition, male patients receiving Novo Mix 30 experienced a significantly increased hypoglycemic duration compared to those of receiving Humalog Mix 50 (0 (0, 4.8) vs. 0 (0, 0).

Conclusion: Our data indicate that male patients with T2D receiving mid-premixed insulin analogue regimen may have a potential benefit of improvement in glycemic control compared to female patients. This trial is registered with ClinicalTrials.gov ChiCTR-IPR-15007340.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Study flow chart.
Figure 2
Figure 2
The average blood glucose concentrations per hour in all patients. ∗p < 0.05.
See this image and copyright information in PMC

References

    1. Kalra S., Czupryniak L., Kilov G., et al. Expert opinion: patient selection for premixed insulin formulations in diabetes care. Diabetes Therapy. 2018;9(6):2185–2199. doi: 10.1007/s13300-018-0521-2. - DOI - PMC - PubMed
    1. Jia W., Xiao X., Ji Q., et al. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial. The Lancet Diabetes & Endocrinology. 2015;3(4):254–262. doi: 10.1016/S2213-8587(15)00041-8. - DOI - PubMed
    1. Su Q., Liu C., Zheng H., et al. Comparison of insulin lispro mix 25 with insulin lispro mix 50 as insulin starter in Chinese patients with type 2 diabetes mellitus (CLASSIFY study): subgroup analysis of a phase 4 open-label randomized trial. Journal of Diabetes. 2017;9(6):575–585. doi: 10.1111/1753-0407.12442. - DOI - PubMed
    1. Li F. F., Liu B. L., Zhu H. H., et al. Continuous glucose monitoring in newly diagnosed type 2 diabetes patients reveals a potential risk of hypoglycemia in older men. Journal of Diabetes Research. 2017;2017:8. doi: 10.1155/2017/2740372.2740372 - DOI - PMC - PubMed
    1. Li F. F., Zhang Y., Zhang W. L., et al. Male patients with longstanding type 2 diabetes have a higher incidence of hypoglycemia compared with female patients. Diabetes Therapy. 2018;9(5):1969–1977. doi: 10.1007/s13300-018-0492-3. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances